UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended July 4, 2010

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

____

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

YES x NO o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES x NO o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (check one):

Large Accelerated filer x

Accelerated filer o

Non-accelerated filer o

Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES o NO x

At August 9, 2010, 8,038,278,387 shares of the issuer s voting common stock were outstanding.

FORM 10-Q

For the Quarter Ended

July 4, 2010

Table of Contents

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Income for the three and six months ended July 4, 2010, and June 28, 2009

Condensed Consolidated Balance Sheets as of July 4, 2010, and December 31, 2009

Condensed Consolidated Statements of Cash Flows for the six months ended July 4, 2010, and June 28, 2009

Notes to Condensed Consolidated Financial Statements

Review Report of Independent Registered Public Accounting Firm

22

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

23

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

54

Item 4.

Controls and Procedures

54

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

55

Item 1A.

Risk Factors

59

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

59

Item 3.

Defaults Upon Senior Securities

59

Item 5.

Other Information

59

Item 6.

Exhibits

59

Signature

60

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

Six Months Ended

(MILLIONS, EXCEPT PER COMMON SHARE DATA)

July 4,

2010

June 28,

2009

July 4,

2010

June 28,

2009

Revenues

17,327

10,984

34,077

21,851

Costs and expenses:

Cost of sales(a)

3,795

1,756

8,101

3,164

Selling, informational and administrative expenses(a)

4,807

3,350

9,243

6,226

Research and development expenses(a)

2,187

1,695

4,413

3,400

Amortization of intangible assets

1,407

583

2,816

1,161

Acquisition-related in-process research and development charges

20

74

20

Restructuring charges and certain acquisition-related costs

886

459

1,592

1,013

Other deductions net

271

72

685

15

Income from continuing operations before provision for taxes on income

3,974

3,049

7,153

6,852

Provision for taxes on income

1,488

786

2,634

1,860

Income from continuing operations

2,486

2,263

4,519

4,992

Discontinued operations net of tax

(1

Net income before allocation to noncontrolling interests

2,485

2,266

4,520

4,996

Less: Net income attributable to noncontrolling interests

10

19

Net income attributable to Pfizer Inc.

2,475

2,261

4,501

4,990

Earnings per share basic:

Income from continuing operations attributable to Pfizer Inc.

common shareholders

0.31

0.34

0.56

0.74

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.31

0.34

0.56

0.74

Earnings per share diluted:

Income from continuing operations attributable to Pfizer Inc.

common shareholders

0.31

0.34

0.56

0.74

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.31

0.34

0.56

0.74

Weighted-average shares used to calculate earnings per common share:

Basic

8,046

6,728

8,053

6,726

Diluted

8,072

6,752

8,085

6,752

Cash dividends paid per common share

0.18

0.16

0.36

0.48

(a)

Exclusive of amortization of intangible assets, except as disclosed inNote 9B. Goodwill and Other Intangible Assets: Other Intangible Assets.

See accompanying Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(millions of dollars)

July 4,

2010*

Dec. 31,

2009**

Assets

Cash and cash equivalents

1,877

1,978

Short-term investments

17,391

23,991

Accounts receivable, less allowance for doubtful accounts

14,012

14,645

Short-term loans

515

1,195

Inventories

9,511

12,403

Current deferred tax assets and other current assets

7,113

6,962

Assets held for sale

682

496

Total current assets

51,101

61,670

Long-term investments and loans

10,524

13,122

Property, plant and equipment, less accumulated depreciation

20,041

22,780

Goodwill

43,142

42,376

Identifiable intangible assets, less accumulated amortization

62,231

68,015

Noncurrent deferred tax assets and other noncurrent assets

4,032

4,986

Total assets

191,071

212,949

Liabilities and Shareholders Equity

Short-term borrowings, including current portion of long-term debt

5,509

5,469

Accounts payable

3,078

4,370

Dividends payable

1,450

1,454

Income taxes payable

727

10,107

Accrued compensation and related items

1,789

2,242

Current deferred tax liabilities and other current liabilities

12,128

13,583

Total current liabilities

24,681

37,225

Long-term debt

37,765

43,193

Pension benefit obligations

5,969

6,392

Postretirement benefit obligations

3,246

3,243

Noncurrent deferred tax liabilities

17,344

17,839

Other taxes payable

9,538

9,000

Other noncurrent liabilities

5,650

5,611

Total liabilities

104,193

122,503

Preferred stock

56

61

Common stock

443

443

Additional paid-in capital

70,568

70,497

Employee benefit trusts

(25

(333

Treasury stock

(22,206

(21,632

Retained earnings

42,010

40,426

Accumulated other comprehensive (loss)/income

(4,407

552

Total Pfizer Inc. shareholders equity

86,439

90,014

Equity attributable to noncontrolling interests

439

432

Total shareholders equity

86,878

90,446

Total liabilities and shareholders equity

191,071

212,949

Unaudited.

**

Condensed from audited financial statements.

See accompanying Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Six Months Ended

(millions of dollars)

July 4,

2010

June 28,

2009

Operating Activities:

Net income before allocation to noncontrolling interests

4,520

4,996

Adjustments to reconcile net income before allocation to noncontrolling interests to net

cash (used in)/provided by operating activities:

Depreciation and amortization

4,264

2,014

Share-based compensation expense

243

169

Asset write-offs and impairment charges

833

270

Acquisition-related in-process research and development charges

74

20

Deferred taxes from continuing operations

1,610

731

Other non-cash adjustments

(92

(292

Changes in assets and liabilities, net of acquisitions and divestitures

(12,939

(247

Net cash (used in)/provided by operating activities

(1,487

7,661

Investing Activities:

Purchases of property, plant and equipment

(678

(522

Purchases of short-term investments

(3,531

(38,900

Proceeds from redemptions and sales of short-term investments

11,048

14,251

Purchases of long-term investments

(1,481

(5,266

Proceeds from redemptions and sales of long-term investments

3,156

3,484

Other investing activities

519

346

Net cash provided by/(used in) investing activities

9,033

(26,607

Financing Activities:

Increase in short-term borrowings

3,169

21,754

Principal payments on short-term borrowings

(7,321

(22,493

Proceeds from issuances of long-term debt

23,996

Principal payments on long-term debt

(2

(908

Purchases of common stock

(500

Cash dividends paid

(2,995

(3,200

Other financing activities

77

(106

Net cash (used in)/provided by financing activities

(7,572

19,043

Effect of exchange-rate changes on cash and cash equivalents

(75

25

Net (decrease)/increase in cash and cash equivalents

(101

122

Cash and cash equivalents at beginning of period

1,978

2,122

Cash and cash equivalents at end of period

1,877

2,244

Supplemental Cash Flow Information:

Cash paid during the period for:

Income taxes

11,311

1,109

Interest

1,342

299

See accompanying Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation

We prepared the condensed consolidated financial statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three-month and six-month periods ended May 30, 2010, and May 24, 2009.

On October 15, 2009, we completed our acquisition of Wyeth and, commencing from the acquisition date, our financial statements include the assets, liabilities, operating results and cash flows of Wyeth. As a result, legacy Wyeth operations are reflected in our results of operations for the second-quarter and six-month 2010 periods, but not for the second-quarter and six-month 2009 periods. Also, legacy Wyeth cash flows are reflected for the six-month period in 2010, but not for the six-month period in 2009.

Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

We are responsible for the unaudited financial statements included in this document. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results.

The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2009.

Note 2. Adoption of New Accounting Policies

The provisions of the following new accounting standards were adopted as of January 1, 2010 and did not have a significant impact on our consolidated financial statements:

An amendment to the recognition and measurement guidance for the transfers of financial assets.

An amendment to the guidelines for determining the primary beneficiary in a variable interest entity.

Note 3. Acquisition of Wyeth

On October 15, 2009 (the acquisition date), we acquired all of the outstanding equity of Wyeth in a cash-and-stock transaction, valued at the acquisition date at approximately $68 billion. While Wyeth now is a wholly owned subsidiary of Pfizer, the merger of local Pfizer and Wyeth entities may be pending or delayed in various international jurisdictions and integration in these jurisdictions is subject to completion of various local legal and regulatory obligations.

Recording of Assets Acquired and Liabilities Assumed

The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date, as well as adjustments made in the first six months of 2010 to the amounts initially recorded in 2009 (measurement period adjustments). The measurement period adjustments did not have a significant impact on our consolidated statements of income, balance sheets or cash flows in any period and, therefore, we have not retrospectively adjusted our financial statements. Certain estimated values are not yet finalized (see below) and are subject to change, which could be significant. We will finalize the amounts recognized as we obtain the information necessary to complete the analyses, but no later than one year from the acquisition date.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(millions of dollars)

Amounts Recognized

as of Acquisition

Date(a)

Measurement

Period

Adjustments

Amounts Recognized

as of Acquisition Date

(as adjusted)

Working capital, excluding inventories

16,342

73

16,415

Inventories

8,388

(172

8,216

Property, plant and equipment

10,054

(198

9,856

Identifiable intangible assets, excluding

in-process research and development(b)

37,595

(517

37,078

In-process research and development(b)

14,918

(875

14,043

Other noncurrent assets

2,394

2,394

Long-term debt

(11,187

(11,187

Benefit obligations

(3,211

36

(3,175

Net tax accounts(c)

(24,773

(105

(24,878

Other noncurrent liabilities

(1,908

(75

(1,983

Total identifiable net assets

48,612

(1,833

46,779

Goodwill(d)

19,954

1,833

21,787

Net assets acquired

68,566

68,566

Less: Amounts attributable to

noncontrolling interests

(330

(330

Total consideration transferred

68,236

68,236

(a)

As previously reported in Pfizer s 2009 Annual Report on Form 10-K.

(b)

The measurement period adjustments for Identifiable intangible assets primarily consist of adjustments recorded to reflect changes in the estimated fair value of certain acquired intangibles, principally in-process research and development assets. These adjustments were made largely to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date.

(c)

The measurement period adjustments for Net tax accounts primarily reflect the tax impact of the pre-tax measurement period adjustments offset by adjustments to uncertain tax positions following receipt of additional information from taxing authorities about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date.

(d)

Goodwill recognized as of the acquisition date (as adjusted) totaled $18,670 million for our Biopharmaceutical segment and $3,117 million for our Diversified segment. These amounts are not yet finalized and are subject to change.

The recorded amounts are provisional and subject to change. Specifically, the following items are subject to change:

Amounts for intangibles and inventory, pending finalization of valuation efforts.

Amounts for legal contingencies, pending the finalization of our examination and evaluation of the portfolio of filed cases.

Amounts for income tax assets, receivables and liabilities pending the filing of Wyeth pre-acquisition tax returns, including all required disclosures and documentation, as well as the receipt of information from taxing authorities, which may change certain estimates and assumptions used.

The allocation of goodwill among reporting units.

Note 4. Cost-Reduction Initiatives and Acquisition-Related Costs

We have incurred significant costs in connection with our cost-reduction initiatives (several programs initiated since 2005) and our acquisition of Wyeth on October 15, 2009.

Since the acquisition of Wyeth, our cost-reduction initiatives that were announced on January 26, 2009, but not completed as of December 31, 2009, have been incorporated into a comprehensive plan to integrate Wyeth s operations, generate cost savings and capture synergies across the combined company. We are focusing our efforts on achieving an appropriate cost structure for the combined company.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

We incurred the following costs in connection with all of our cost-reduction initiatives and the acquisition of Wyeth:

Three Months Ended

Six Months Ended

(millions of dollars)

July 4,

2010

June 28,

2009

July 4,

2010

June 28,

2009

Transaction costs(a)

184

13

553

Integration costs(b)

211

101

419

129

Restructuring charges(c)

671

174

1,160

331

Restructuring charges and certain acquisition-related costs

886

459

1,592

1,013

Additional depreciation asset restructuring(d)

215

61

308

151

Implementation costs(e)

95

179

Total

1,101

615

1,900

1,343

(a)

Transaction costs represent external costs directly related to our acquisition of Wyeth and primarily include expenditures for banking, legal, accounting and other similar services. Substantially all of the costs incurred in the second quarter and first six months of 2009 were fees related to a $22.5 billion bridge term loan credit agreement entered into with certain financial institutions on March 12, 2009 to partially fund our acquisition of Wyeth. The bridge term loan credit agreement was terminated in June 2009 as a result of our issuance of approximately $24.0 billion of senior unsecured notes in the first half of 2009.

(b)

Integration costs represent external, incremental costs directly related to integrating Wyeth and primarily include expenditures for consulting and systems integration.

(c)

Restructuring charges include the following:

Costs Incurred

Three Months Ended

Six Months Ended

Activity

Accrual

(millions of dollars)

July 4,

2010

June 28,

2009

July 4,

2010

June 28,

2009

2005-2010

Through

July 4,

2010(1)

As of

July 4,

2010(2)

Employee termination costs

118

29

576

164

8,297

6,000

2,297

Asset impairments

497

73

503

91

1,955

1,955

Other

56

72

81

76

791

657

134

Total restructuring charges

671

174

1,160

331

11,043

8,612

2,431

(1)

Includes adjustments for foreign currency translation.

(2)

Included in Current deferred tax liabilities and other current liabilities ($1.6 billion) and Other noncurrent liabilities ($831 million).

Restructuring charges in 2010 are related to the integration of Wyeth. From the beginning of our cost-reduction initiatives in 2005 through July 4, 2010, Employee termination costs represent the expected reduction of the workforce by approximately 47,400 employees, mainly in manufacturing, sales and research, of which approximately 29,100 employees have been terminated as of July 4, 2010. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. Asset impairments primarily include charges to write down property, plant and equipment to fair value. Other primarily includes costs to exit certain assets and activities.

(d)

Additional depreciation asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions and are included in our condensed consolidated statements of income as follows:

Three Months Ended

Six Months Ended

(millions of dollars)

July 4,

2010

June 28,

2009

July 4,

2010

June 28,

2009

Cost of sales

113

32

126

95

Selling, informational and administrative expenses

102

162

14

Research and development expenses

21

20

42

Total

215

61

308

151

(e)

Implementation costs in the three months and six months ended June 28, 2009 represent external, incremental costs directly related to implementing cost-reduction initiatives prior to our acquisition of Wyeth, and primarily include expenditures related to system and process standardization and the expansion of shared services. For the three months ended June 28, 2009, implementation costs are included in Cost of sales ($13 million), Selling, informational and administrative expenses ($77 million), Research and development expenses ($11 million) and Other deductions net ($6 million income). For the six months ended June 28, 2009, implementation costs are included in Cost of sales ($26 million), Selling, informational and administrative expenses ($117 million), Research and development expenses ($31 million) and Other deductions net ($5 million).

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 5. Taxes on Income

Our effective tax rate for continuing operations was 37.4% for the second quarter of 2010, compared to 25.8% for the second quarter of 2009, and 36.8% for the first six months of 2010, compared to 27.1% for the first six months of 2009. The higher tax rates in the second quarter and first six months of 2010 are primarily the result of:

higher charges, incurred as a result of our acquisition of Wyeth, and the mix of jurisdictions in which those charges were incurred, and

the expiration of the U.S. research and development tax credit.

The effective tax rate for the first six months of 2010 was additionally impacted by the write-off of the deferred tax asset of approximately $270 million related to the Medicare Part D subsidy for retiree prescription drug coverage, resulting from changes in the U.S. healthcare legislation enacted in March 2010 concerning the tax treatment of that subsidy effective for tax years beginning after December 31, 2012, partially offset by $410 million in tax benefits for the resolution of certain tax positions pertaining to prior years with various foreign tax authorities.

Note 6. Comprehensive Income/(Loss)

The components of comprehensive income/(loss) follow:

Three Months Ended

Six Months Ended

(millions of dollars)

July 4,

2010

June 28,

2009

July 4,

2010

June 28,

2009

Net income before allocation to noncontrolling interests

2,485

2,266

4,520

4,996

Other comprehensive income/(loss):

Currency translation adjustment and other

(2,144

2,638

(4,891

2,254

Net unrealized losses on derivative financial instruments

(375

(144

(241

(167

Net unrealized gains/(losses) on available-for-sale securities

(97

81

(112

226

Benefit plan adjustments

167

18

284

177

Total other comprehensive income/(loss)

(2,449

2,593

(4,960

2,490

Total comprehensive income/(loss) before allocation to

noncontrolling interests

36

4,859

(440

7,486

Less: Comprehensive income attributable to

noncontrolling interests

27

12

18

14

Comprehensive income/(loss) attributable to Pfizer Inc.

4,847

(458

7,472

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 7. Financial Instruments

A. Selected Financial Assets and Liabilities

Information about certain of our financial assets and liabilities follows:

(millions of dollars)

July 4,

2010

Dec. 31,

2009

Selected financial assets measured at fair value on a recurring basis(a) :

Trading securities(b)

162

184

Available-for-sale debt securities(c)

24,110

32,338

Available-for-sale money market funds(d)

1,458

2,569

Available-for-sale equity securities, excluding money market funds(c)

183

281

Derivative financial instruments in receivable positions(e):

Foreign currency swaps

113

798

Interest rate swaps

534

276

Foreign currency forward-exchange contracts

404

502

Total

26,964

36,948

Other selected financial assets(f):

Short-term loans, carried at cost(g)

515